EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Morihito Okada iD, Shunichi Sugawara iD, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F Chen-Yoshikawa, Yasushi Goto iD, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu iD

Cancer Science · 2025

DOI: 10.1111/cas.70297 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Science, 2025. Verfasst von Morihito Okada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche, Chugai Pharmaceutical Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). We report updated efficacy and safety results from the disease‐free survival (DFS) final and overall survival (OS) second interim analyses, with ≥ 5 years of follow‐up in Japanese patients. Patients who received 1–4 21‐day chemotherapy cycles after surgery were randomized 1:1 to receive atezolizumab 1200 mg every 3 weeks (≤ 16 cycles) or BSC. Of 149 patients enrolled, 117 were randomized to the intention‐to‐treat (ITT) population (atezolizumab n = 59; BSC n = 58). At data cutoff (January 26, 2024), unstratified hazard ratios (HRs) (95% confidence interval [CI]) for DFS in the atezolizumab versus BSC arms were 0.54 (0.28–1.07) in the stage II–IIIA programmed death‐ligand 1 (PD‐L1) tumor cell (TC) ≥ 1% ( n = 74), 0.64 (0.27–1.52) in the stage II–IIIA PD‐L1 TC 1%–49% ( n = 34), 0.52 (0.17–1.54) in the stage II–IIIA PD‐L1 TC ≥ 50% ( n = 40), 0.58 (0.34–1.00) in the stage II–IIIA all‐randomized ( n = 113), and 0.57 (0.34–0.98) in the ITT populations. OS remained immature; median OS was not reached in both treatment arms for all subgroups. Grade 3/4 adverse events occurred in 15 (26.8%) and 7 patients (12.1%) in the atezolizumab and BSC arms, respectively; no deaths were reported. In this exploratory subgroup analysis, adjuvant atezolizumab demonstrated numerically improved DFS and OS versus BSC in Japanese patients and was well tolerated, similar to the global IMpower010 population. Trial Registration: ClinicalTrials.gov identifier: NCT02486718

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedAgedNeoplasm StagingAdultJapanTreatment OutcomeDisease-Free SurvivalChemotherapy, AdjuvantEast Asian People

Stichwörter der Autor:innen

Japanadjuvantatezolizumabimmune checkpoint inhibitornon‐small cell lung cancer

Substanzen

atezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Division of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
  • Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Morihito Okada, Shunichi Sugawara, Yasushi Goto, Hirotsugu Kenmotsu

Förderung

  • F. Hoffmann-La Roche
  • Chugai Pharmaceutical Co. Ltd

Zitieren

APA

Okada, M., Sugawara, S., Watanabe, Y., Saito, H., Chen-Yoshikawa, T. F., Goto, Y., Nishio, W., Nakagawa, S., Hayashi, M., & Kenmotsu, H. (2025). IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70297

Vancouver

Okada M, Sugawara S, Watanabe Y, Saito H, Chen-Yoshikawa TF, Goto Y, et al. IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer. Cancer Science. 2025. doi:10.1111/cas.70297

BibTeX
@article{Okada2025,
  author = {Okada, Morihito and Sugawara, Shunichi and Watanabe, Yasutaka and Saito, Haruhiro and Chen-Yoshikawa, Toyofumi F and Goto, Yasushi and Nishio, Wataru and Nakagawa, Shizuka and Hayashi, Morihiko and Kenmotsu, Hirotsugu},
  title = {IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70297}
}
Kostenlos starten →